Preparation and characteristics of DNA-nanoparticles targeting to hepatocarcinoma cells

Table 2 Distribution (%) of ³²P-DNA in mice after intravenous administration of ³²P-DNA-PLGA nanoparticles (n = 5)

Time	Heart	Liver	Spleen	Lung	Kidney	Blood
5 min	2.22 ± 0.51	57.32 ± 2.36	2.96 ± 0.69	8.29 ± 1.33	16.58 ± 2.02	12.63 ± 1.24
15 min	3.52 ± 0.64	69.69 ± 3.32	3.19 ± 0.58	5.77 ± 0.55	13.87 ± 0.99	3.96 ± 0.36
30 min	2.38 ± 0.67	73.37 ± 3.62	7.55 ± 1.03	3.64 ± 0.41	11.28 ± 1.28	1.78 ± 0.65
1 h	2.08 ± 0.54	80.14 ± 4.56	3.37 ± 0.67	3.08 ± 0.62	9.34 ± 0.68	1.99 ± 0.54
2 h	2.59 ± 0.28	78.45 ± 4.02	3.73 ± 0.76	5.35 ± 0.58	8.36 ± 0.94	1.47 ± 0.23
6 h	3.18 ± 0.60	75.03 ± 3.69	7.38 ± 1.03	3.74 ± 0.39	9.61 ± 0.96	1.06 ± 0.24
12 h	2.21 ± 0.51	69.34 ± 3.96	6.17 ± 1.24	7.88 ± 0.64	10.17 ± 1.04	4.22 ± 0.32
24 h	1.94 ± 0.32	65.59 ± 3.25	6.46 ± 1.04	7.95 ± 0.57	12.10 ± 1.23	5.96 ± 0.59
48 h	2.21 ± 0.29	61.18 ± 2.69	7.01 ± 0.48	9.27 ± 0.71	12.87 ± 0.86	6.46 ± 0.86
72 h	2.51 ± 0.37	60.56 ± 2.98	6.45 ± 0.69	9.98 ± 0.65	13.54 ± 1.11	6.96 ± 0.75